This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spectrum Pharmaceuticals, Inc.
Drug Names(s): LFA, Levofolinic Acid, Isovorin, ISO-Vorin, LEVOleucovorin
Description: Levofolinic acid is a pure active isomer of Leucovorin (folinic acid). Leucovorin calcium (folinic acid) is a reduced form of folic acid. Folic acid participates in several key biological processes, including the synthesis of DNA, RNA and proteins. It is necessary for DNA replication and repair, the maintenance of the integrity of the genome, and is involved in the regulation of gene expression, among other things.
Leucovorin is usually used 24 hours aftermethotrexate to selectively “rescue” normal cells from the adverse effects of methotrexatecaused by inhibition of production of reduced folates. It is not used simultaneously withmethotrexate, as it might then nullify the therapeutic effect of the methotrexate. More recently,leucovorin has also been used to enhance the activity of fluorouracil by binding to the enzymethymidylate synthetase and decreasing intracellular levels of thymidylate. Commerciallyavailable leucovorin is the racemic mixture of D and L isomers; the L stereoisomer is the activemoiety.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In April 2006, Spectrum acquired all of the oncology drug product assets of Targent. Spectrum acquired the rights for sales and marketing of levofolinic acid (LFA) in the U.S., Canada and Mexico, along with several other oncology drugs in various stages of development. LFA is currently marketed by Wyeth, Sanofi-Aventis and others in certain parts of the world, including Europe and Japan.
Under the terms of the agreement, Spectrum issued to Targent an aggregate amount of 600,000 shares of common stock at closing. In addition, Targent is eligible to receive payments, in the form of our common stock and/or cash, upon achievement of certain regulatory and sales milestones, if any. At Spectrum's option, any amounts due in cash under the purchase agreement may be paid by issuing shares of common stock having a value equal to the cash payment amount.
In May 2006, Spectrum entered into a manufacturing and supply agreement with...See full deal structure in Biomedtracker
Partners: Sanofi Pfizer Inc.
Additional information available to subscribers only: